Human JAM-A Biotinylated Antibody
Human JAM-A Biotinylated Antibody Summary
Accession # Q9Y624
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
The family of junctional adhesion molecules (JAM), comprising at least three members, are type I transmembrane receptors belonging to the immunoglobulin (Ig) superfamily (1, 2). These proteins are localized in the tight junctions between endothelial or epithelial cells. Some family members are also found on blood leukocytes and platelets. Human JAM-A, also known as platelet adhesion molecule 1 (PAM-1) and platelet F11 receptor (3), is predominantly expressed at intercellular junctions of both epithelial cells and endothelial cells (1‑4). It is also expressed on circulating blood cells including neutrophils, monocytes, platelets, erythrocytes and lymphocytes (5). Human JAM-A cDNA predicts a 299 amino acid (aa) residue precursor protein with a putative 27 aa signal peptide, a 210 aa extracellular region containing two Ig‑like V-subset domains, a 24 aa transmembrane domain and a 38 aa cytoplasmic domain. The human and mouse proteins share approximately 67% aa sequence homology. Human JAM-A also shares approximately 35% and 32% aa sequence homology with human JAM-B and JAM-C, respectively. JAM-A exhibits homophilic interactions to regulate tight junction assembly and modulate paracellular permeability. This homophilic interation also mediates platelet aggregation and adhesion to endothelial cells and may play a role in thrombosis (3). JAM-A binds heterotypically with the beta 2 integrin lymphocyte function-associated antigen-1 (LFA-1). This JAM‑A‑LFA‑1 interaction is involved in leukocyte adhesion and transmigration (6). JAM-A has also been shown to bind reovirus attachment protein sigma-1 to permit reovirus infection and signal virus-induced apoptosis (7).
- Chavakis, T. et al. (2003) Thromb. Haemost. 89:13.
- Aurand-Lions, M. et al. (2001) Blood 98:3699.
- Sobocka, M.B. et al. (2000) Blood 95:2600.
- Martin-Padura, I. et al. (1998) J. Cell Biol. 142:117.
- Williams, L.A. et. al. (1999) Mol. Immunol. 36:1175.
- Ostermann, G. et al. (2002) Nature Immunol. 3:151.
- Barton, E.S. et al. (2001) Cell 104:441.
Citations for Human JAM-A Biotinylated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
Citations: Showing 1 - 2
Filter your results:
JAM-A and ALCAM are therapeutic targets to inhibit diapedesis across the BBB of CD14+CD16+ monocytes in HIV-infected individuals.
Authors: Williams D, Anastos K, Morgello S, Berman J
J Leukoc Biol, 2014-11-24;97(2):401-12.
Sample Types: Plasma
Applications: ELISA Development (Detection)
Evaluation of soluble junctional adhesion molecule-A as a biomarker of human brain endothelial barrier breakdown.
Authors: Haarmann A, Deiss A, Prochaska J, Foerch C, Weksler B, Romero I, Couraud PO, Stoll G, Rieckmann P, Buttmann M
PLoS ONE, 2010-10-21;5(10):e13568.
Sample Types: Serum
Applications: ELISA Development
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Supplemental Cell Selection Products
Supplemental ELISA Products
Reviews for Human JAM-A Biotinylated Antibody
There are currently no reviews for this product. Be the first to review Human JAM-A Biotinylated Antibody and earn rewards!
Have you used Human JAM-A Biotinylated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image